Interv Akut Kardiol. 2018;17(3):138-139

Stabilní ischemická choroba srdeční a role perkutánních koronárních intervencí

Michael Želízko
Klinika kardiologie IKEM, Praha

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Želízko M. Stabilní ischemická choroba srdeční a role perkutánních koronárních intervencí. Interv Akut Kardiol. 2018;17(3):138-139.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Windecker S, Stortecky S, Stefanini GG, et al. Revascularization versus medical treatment in patients withstable coronary artery disease: network metaanalysis. BMJ 2014; 348: g3859. Go to original source... Go to PubMed...
    2. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516. Go to original source...
    3. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from tle clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283-1291. Go to original source...
    4. Xaplanteris P, Fournier S, Pijls NH, et al. Five year outcomes with PCI guided by fractional flow reserve. N Engl J Med 2018; 379: 250-259. Go to original source...
    5. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double blind, randomized controlled trial. Lancet 2018; 391: 31-40. Go to original source...
    6. Al-Lamee R: ORBITA continues to surprise: 85 % of sham arm opted for PCI when trial ended. Oral communication, SCAI, April 26, 2018.
    7. Hennigan GZ. FFR: a randomized controlled trial of PCI vs optimal medical therapy in patients with stable angina and Grey Zone fractional flow reserve values. Oral communication, EuroPCR 2018, May 22, 2018.
    8. Haude M on behalf of PCR and EAPCI: PCR statement on PCI treatment for chronic coronary syndrome (CCS). Oral communication. EuroPCR 2018, May 22, 2018.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.